SOX plus sintilimab vs P-SOX vs SOX as neoadjuvant therapy in advanced gastric cancer: Efficacy and safety

Figure 1 Comparison of overall survival and progression-free survival among the three groups. A: Overall survival; B: Progression-free survival. OS: Overall survival; PFS: Progression-free survival.

Figure 2 Progression-free survival nomogram. PFS: Progression-free survival; RECIST: Response Evaluation Criteria in Solid Tumors; TRG: Tumor regression grade.

Figure 3 Progression-free survival receiver operating characteristic curve. A: Training set; B: Validation set; C: Concordance index over time. AUC: Area under the curve.

Figure 4 Calibration curve for progression-free survival. A: Training set; B: Validation set. PFS: Progression-free survival.

Figure 5 Decision curve analysis curves of progression-free survival. A: 18-month progression-free survival (PFS), training set; B: 24-month PFS, training set; C: 36-month PFS, training set; D: 18-month PFS, validation set; E: 24-month PFS, validation set; F: 36-month PFS, validation set.

Figure 6 Kaplan-Meier survival curves for the verification of risk stratification. A: Training set; B: Validation set; C: Total set. PFS: Progression-free survival.